Multikinase Inhibitor (Tyrosine and Serine/Threonine Kinase Inhibitor) for the Treatment of Severe Pulmonary Arterial Hypertension

Multikinase Inhibitor (Tyrosine and Serine/Threonine Kinase Inhibitor) for the Treatment of Severe Pulmonary Arterial Hypertension - Multikinase Inhibitor for Pulmonary Arterial Hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001709

Enrollment

Registered

2009-02-16

Start date

2009-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypertension

Interventions

administration of sorafenib, which is the multikinase inhibitor (tyrosine and serine/threonine kinase inhibitor)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with severe pulmonary arterial hypertension who are refractory for conventional therapies such as PGIS, Ca-blocker, bosentan, and sildenafil

Exclusion criteria

Exclusion criteria: patients who can not express subjective symptoms, can not be evaluated through objective improvement, have the past history of thromboembolism, have the systemic hypertensive disease, have critical liver cirrhosis, are during pregnancy or during lactation, have critical left heart disease, or are receiving hemodialysis.

Design outcomes

Primary

Measure	Time frame
subjective symptom (WHO functional classification), 6 minutes walk test, echocardiography, right heart catheterization, serum BNP level	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026